 | |
| Clinical data | |
|---|---|
| Other names | 2,3,4-Trimethoxyphenethylamine; 2,3,4-TMPEA; TMPEA-3; 2C-TMA-3 |
| Routes of administration | Oral [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17NO3 |
| Molar mass | 211.261 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Isomescaline (IM), also known as 2,3,4-trimethoxyphenethylamine (2,3,4-TMPEA) or as TMPEA-3 or 2C-TMA-3, is a chemical compound related to mescaline (3,4,5-trimethoxyphenethylamine). [1] It is a positional isomer of mescaline, as well as an analogue of TIM-2, TIM-3, and TIM-4. [1] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists its dose as greater than 400 mg orally and its duration as unknown. [1] Despite its structural similarity to mescaline, isomescaline produced no effects in humans. [1] Very little data exists about the pharmacological properties, metabolism, and toxicity of isomescaline. [1] Isomescaline was first described in the scientific literature by Clark and colleagues by 1965. [2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991. [1]
